PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35605433-4	2022	The results showed that DMF suppressed the activation of NLRP3 inflammasome activation in lipopolysaccharide-primed murine bone marrow-derived macrophages upon ATP or nigericin treatment, as evidenced by reduced cleavage of pro-caspase-1, release of mature interleukin-1beta (IL-1beta) and generation of gasdermin D N-terminal fragment (GSDMD-NT).	Dimethyl Fumarate	24-27	gasdermin D	Mus musculus	304-315	
35605433-6	2022	Consistent with reduced generation of GSDMD-NT, ATP or nigericin-induced pyroptosis was markedly suppressed by DMF.	Dimethyl Fumarate	111-114	gasdermin D	Mus musculus	38-43	
35605433-10	2022	Importantly, DMF decreased serum levels of inflammatory cytokines and ameliorated liver injury in Con A-induced AIH of mice, concomitant with reduced the generation of caspase-1p10 and GSDMD-NT and alleviating mitochondrial aggregation in the liver.	Dimethyl Fumarate	13-16	gasdermin D	Mus musculus	185-190	
35605433-4	2022	The results showed that DMF suppressed the activation of NLRP3 inflammasome activation in lipopolysaccharide-primed murine bone marrow-derived macrophages upon ATP or nigericin treatment, as evidenced by reduced cleavage of pro-caspase-1, release of mature interleukin-1beta (IL-1beta) and generation of gasdermin D N-terminal fragment (GSDMD-NT).	Dimethyl Fumarate	24-27	gasdermin D	Mus musculus	337-342	
35228524-16	2022	In addition, pyroptosis inhibitor DMF not only alleviated kidney injury of CS-AKI mice but also inhibited macrophage polarization to M1 phenotype and pyroptosis via the RIG-I/Caspase1/GSDMD signaling pathway.	Dimethyl Fumarate	34-37	gasdermin D	Mus musculus	184-189	
32820063-3	2020	We found that dimethyl fumarate (DMF) delivered to cells or endogenous fumarate reacts with gasdermin D (GSDMD) at critical cysteine residues to form S-(2-succinyl)-cysteine.	Dimethyl Fumarate	14-31	gasdermin D	Mus musculus	92-103	
35153737-4	2021	Dimethyl fumarate (DMF) was used as the GSDMD N-terminal fragments (GSDMD-N) inhibitor and suspended in 0.5% sodium carboxymethyl cellulose (CMC) for orally administration.	Dimethyl Fumarate	0-17	gasdermin D	Mus musculus	40-45	
35153737-4	2021	Dimethyl fumarate (DMF) was used as the GSDMD N-terminal fragments (GSDMD-N) inhibitor and suspended in 0.5% sodium carboxymethyl cellulose (CMC) for orally administration.	Dimethyl Fumarate	19-22	gasdermin D	Mus musculus	40-45	
32820063-3	2020	We found that dimethyl fumarate (DMF) delivered to cells or endogenous fumarate reacts with gasdermin D (GSDMD) at critical cysteine residues to form S-(2-succinyl)-cysteine.	Dimethyl Fumarate	14-31	gasdermin D	Mus musculus	105-110	
32820063-3	2020	We found that dimethyl fumarate (DMF) delivered to cells or endogenous fumarate reacts with gasdermin D (GSDMD) at critical cysteine residues to form S-(2-succinyl)-cysteine.	Dimethyl Fumarate	33-36	gasdermin D	Mus musculus	92-103	
32820063-3	2020	We found that dimethyl fumarate (DMF) delivered to cells or endogenous fumarate reacts with gasdermin D (GSDMD) at critical cysteine residues to form S-(2-succinyl)-cysteine.	Dimethyl Fumarate	33-36	gasdermin D	Mus musculus	105-110	
32820063-5	2020	In mice, the administration of DMF protects against LPS shock and alleviates familial Mediterranean fever and experimental autoimmune encephalitis (EAE) by targeting GSDMD.	Dimethyl Fumarate	31-34	gasdermin D	Mus musculus	166-171	
32820063-6	2020	Collectively, these findings identify GSDMD as a target of fumarate and reveal a mechanism of action for fumarate-based therapeutics including DMF used to treat multiple sclerosis.	Dimethyl Fumarate	143-146	gasdermin D	Mus musculus	38-43